Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate

Arduino A Mangoni MD, PhD, FRCP, FRACP1, Sara Tommasi PhD1, Angelo Zinellu PhD2, Salvatore Sotgia MSc2, Ciriaco Carru PhD2,3, Matteo Piga MD4, Gian Luca Erre MD5

1Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University and Flinders Medical Centre, Adelaide, Australia; 2Department of Biomedical Sciences, University of Sassari, Sassari, Italy; 3Quality Control Unit, University Hospital (AOUSS), Sassari, Italy; 4Rheumatology Unit, University Clinic and AOU of Cagliari, Italy; 5Rheumatology Unit, Department of Clinical and Experimental Medicine, University Hospital (AOUSS) and University of Sassari, Sassari, Italy

Abstract
About 20% of patients with a history of atherosclerotic cardiovascular disease will experience further cardiovascular events despite maximal pharmacological treatment with cardioprotective drugs. This highlights the presence of residual cardiovascular risk in a significant proportion of patients and the need for novel, more effective therapies. These therapies should ideally target different pathophysiological pathways involved in the onset and the progression of atherosclerosis, particularly the inflammatory and immune pathways. Methotrexate is a first-line disease-modifying antirheumatic drug that is widely used for the management of autoimmune and chronic inflammatory disorders. There is some in vitro and in vivo evidence that methotrexate might exert a unique combination of anti-inflammatory, blood pressure lowering, and vasculoprotective effects. Pending the results of large prospective studies investigating surrogate end-points as well as morbidity and mortality, repurposing methotrexate for cardiovascular risk management might represent a cost-effective strategy with immediate public health benefits. This review discusses the current challenges in the management of cardiovascular disease; the available evidence on the effects of methotrexate on inflammation, blood pressure, and surrogate markers of arterial function; suggestions for future research directions; and practical considerations with the use of methotrexate in this context.

Keywords: arterial function, atherosclerosis, blood pressure, cardiovascular risk, inflammation, methotrexate, repurposing.

Citation
Mangoni AA, Tommasi S, Zinellu A, Sotgia S, Carru C, Piga M, Erre GL. Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate. Drugs in Context 2018; 7: 212557. DOI: 10.7573/dic.212557

Introduction
Atherosclerotic cardiovascular disease, particularly in the form of ischaemic heart disease and stroke, is the leading cause of morbidity and mortality worldwide. In 2013, the global risk of premature death between the ages of 30 and 70 years attributable to cardiovascular disease was 10.8% for men and 6.7% for women. The risk was highest for men in Eastern Europe and for women in Oceania and lowest for both men and women in high-income Asia-Pacific regions. In 2015, ischaemic heart disease was the leading cause of health loss globally, with an estimated 7.3 million acute myocardial infarctions and 110.5 million prevalent cases of ischaemic heart disease. The prevalence of ischaemic heart disease was 290 cases per 100,000 for those 40 to 44 years of age and 11,203 cases per 100,000 for those 75 to 79 years of age. In the same year, there were an estimated 5.4 million acute first-ever ischaemic strokes. The prevalence of stroke was highest for those 74 to 79 years of age.

Significant advances in the understanding of the pathophysiology of atherosclerosis have led to the concept that this disease process is characterized by a state of chronic inflammation, immune activation, and oxidative stress of the arterial wall. There is also good evidence that, at some stage, virtually all cardiovascular risk factors trigger these events, favouring the onset of endothelial dysfunction and vascular damage. For these reasons, barring the recently introduced proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, current cardiovascular drug discovery and development programmes are focused on agents that modulate the inflammatory and immune pathways, in addition
to exhibiting antiatherosclerotic and vasculoprotective effects. However, the identification of such effects in drugs that are currently marketed would avoid the need for expensive, high-risk, and time-consuming drug development programmes, providing at the same time immediate public health benefits.

This review will discuss the presence of residual cardiovascular risk as a key challenge in the contemporary management of atherosclerotic cardiovascular disease, the ongoing search for new antiatherosclerotic agents with additional anti-inflammatory effects, the emerging evidence supporting the potential repurposing of the disease-modifying antirheumatic drug (DMARD) methotrexate in this context, the opportunities for further research in this area, and the practical advantages of methotrexate treatment in the routine management of cardiovascular patients.

Residual cardiovascular risk

Despite maximal treatment with established cardioprotective drug classes, for example, statins, beta-blockers, antiplatelet agents, anticoagulants, angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs), a significant number of patients with a previous atherosclerotic cardiovascular event will experience further events. Stone and colleagues prospectively studied 697 patients with acute coronary syndrome undergoing successful percutaneous coronary intervention. Upon hospital discharge, 97% were on aspirin, 97% on thienopyridines, 85% on statins or other lipid-lowering drugs, 91% on beta-blockers, and 69% on ACE inhibitors or ARBs. Barring thienopyridines, the use of cardioprotective drugs remained high, between 71 and 92%, during the follow up. However, the 3-year cumulative rate of further atherosclerotic cardiovascular events was 20%. Similarly, Kaasenbrood and colleagues assessed the 10-year risk of recurrent vascular events in 6,904 patients with vascular disease. After optimal control of conventional risk factors, as per current guideline recommendations, patients with vascular disease in different arterial territories had a median estimated residual risk of 22% (interquartile range 14 to 36%). Issues with poor treatment adherence in this patient group notwithstanding, the available evidence suggests that approximately one in five patients with high cardiovascular risk and overt atherosclerotic cardiovascular disease will experience further cardiovascular events despite optimal pharmacological management. This observation, and the currently accepted hypothesis that atherosclerosis is an inflammatory state of the arterial wall, has led to the search for novel, more effective agents targeting atherosclerosis.

Targeting inflammation and immunity in atherosclerosis

Under physiological conditions, the endothelium, through the synthesis of the key messenger nitric oxide (NO) by endothelial NO synthase (eNOS), regulates several physiological processes such as vascular tone, arterial stiffness, blood pressure, peripheral vascular resistance, and platelet activity, and it also exerts important antiatherosclerotic effects, including the inhibition of leukocyte adhesion to the arterial wall and the prevention of vascular smooth muscle cell proliferation. According to the ‘inflammatory theory’ of atherosclerosis, the excessive production of pro-atherogenic cytokines, particularly tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), alters the structural and functional integrity of the endothelium, favouring the formation and progression of the atherosclerotic plaque. This has significant biological, as well as clinical, implications as both the presence and the severity of endothelial dysfunction, either singly or in combination with other markers of arterial dysfunction, independently predict adverse cardiovascular outcomes. By contrast, there is good evidence that other cytokines, particularly transforming growth factor-β (TGF-β), interleukin-10 (IL-10), and interleukin-35 (IL-35), exert protective effects against atherogenesis, including the down-regulation of TNF-α and intercellular adhesion molecule-1 (ICAM-1) in endothelial cells.

Current research focuses on the effects of targeted cytokine therapies, that is, anti-IL-1 agents, on surrogate markers of atherosclerosis as well as cardiovascular morbidity and mortality end-points in clinical trials. The introduction of such therapies would represent a significant milestone in the management of cardiovascular risk. However, the agents currently under investigation, albeit marketed for other indications (e.g. the biologic agents adalimumab, etanercept, canakinumab, anakinra, and tocilizumab), are characterized by relatively high costs and potentially serious toxicity. These issues might limit their routine use in a significant number of cardiovascular patients. Studies are also investigating the effects of currently marketed anti-inflammatory drugs, with a wider spectrum of effects on inflammatory and immune pathways, on atherosclerosis and cardiovascular risk.

The following sections will discuss the available evidence regarding the effects of the DMARD methotrexate on cardiovascular outcomes and surrogate markers of atherosclerosis and cardiovascular risk.

Methotrexate and cardiovascular risk: epidemiological evidence

Methotrexate, an analogue of the B-vitamin folic acid, is a first-line synthetic DMARD that is routinely used, at doses between 7.5 and 25 mg weekly, in the management of rheumatoid arthritis and other autoimmune, chronic inflammatory conditions. Epidemiological studies have shown that, when compared to other synthetic DMARDs, methotrexate significantly reduces all-cause mortality in patients with rheumatoid arthritis. Although the mechanisms responsible for this protective effect are unknown, a study has also reported a significant reduction in cardiovascular mortality (hazard ratio [HR] 0.3, 95% confidence interval [CI]: 0.2–0.7), but
not non-cardiovascular mortality (HR 0.6, 95% CI: 0.2–1.2), with methotrexate use.\textsuperscript{25}

Rheumatoid arthritis can be regarded as a human model of chronic systemic inflammation, accelerated atherosclerosis, and vascular damage.\textsuperscript{27} Increased concentrations of pro-atherogenic cytokines TNF-α, IL-1, and IL-6 have been well documented in patients with rheumatoid arthritis.\textsuperscript{29} The cardiovascular risk in rheumatoid arthritis is about two-fold that of the general population and is comparable to the risk in diabetes.\textsuperscript{29} However, in addition to inflammation, traditional risk factors are also involved in the pathophysiology of atherosclerotic cardiovascular disease in rheumatoid arthritis.\textsuperscript{30} There is good evidence that a significant proportion of patients with rheumatoid arthritis, even those without prior evidence of cardiovascular disease, have endothelial dysfunction, altered vascular reactivity, increased platelet activation, dyslipidaemia, and insulin resistance.\textsuperscript{31–35} Furthermore, increased arterial wave reflection and arterial stiffness, and a relatively high prevalence of hypertension, hypercholesterolaemia, obesity, cigarette smoking, type 2 diabetes, and metabolic syndrome, have been reported in this group.\textsuperscript{35–41} From a pathophysiological point of view, a sustained increase in arterial wave reflection, arterial stiffness, and systolic blood pressure causes a significant increase in cardiac afterload. This, in turn, favours the development of left ventricular hypertrophy and dysfunction and independently predicts cardiovascular morbidity and mortality.\textsuperscript{42–44}

The available evidence supporting the hypothesis that methotrexate exerts protective effects against atherosclerotic cardiovascular disease in humans, when compared to other DMARDs, comes from two systematic reviews and meta-analyses. The first, in 66,334 patients with rheumatoid arthritis, psoriasis, or polyarthritis from ten cohort studies, showed that the use of methotrexate was associated with a significantly lower risk of total cardiovascular events (risk ratio [RR] 0.79, 95% CI: 0.73–0.87, p<0.001) and myocardial infarction (RR 0.82, 95% CI: 0.71–0.96, p<0.01). Stronger inverse associations between methotrexate and cardiovascular risk were observed in studies (n=6) that adjusted for underlying disease severity (RR 0.64, 95% CI: 0.43–0.95) and those (n=4) that adjusted for treatment with other DMARDs (RR 0.73, 95% CI: 0.63–0.84).\textsuperscript{45} The second systematic review and meta-analysis reported a significant reduction in total cardiovascular events with methotrexate treatment, when compared to other DMARDs, in eight studies of 65,736 patients with rheumatoid arthritis (RR 0.72, 95% CI: 0.57–0.91, p=0.007). A significant reduction in the risk of myocardial infarction was also observed in a subset of studies (n=3, RR 0.81, 95% CI: 0.68–0.96).\textsuperscript{46} It is important to emphasize that the magnitude of cardiovascular risk reduction observed with methotrexate treatment is similar to that reported in landmark trials of cardioprotective drugs in high-risk patients. For example, in the Heart Outcomes Prevention Evaluation study, the relative risk of total cardiovascular events with the ACE inhibitor ramipril versus placebo was 0.78 (95% CI: 0.70–0.86).\textsuperscript{47} In the West of Scotland Coronary Prevention Study, the relative risk of coronary events (non-fatal myocardial infarction or death from coronary heart disease) with pravastatin treatment versus placebo was 0.69 (95% CI: 0.57–0.83).\textsuperscript{48}

### Methotrexate and cardiovascular risk factors

Several in vitro and in vivo studies have investigated the effects of methotrexate on traditional (e.g. dyslipidaemia, diabetes, hypertension) and emerging (e.g. endothelial dysfunction and arterial stiffness) cardiovascular risk factors. Contrasting results have been reported on the capacity of methotrexate to influence the activity of the cholesterol efflux protein and the concentrations of total cholesterol and different lipoproteins.\textsuperscript{49–60} More recently, a study in cholesterol-fed rabbits receiving combined treatment with lipid core nanoparticles containing paclitaxel and methotrexate showed a significant regression of aortic plaque and intima areas. This was associated with a reduction of macrophage presence in aortic lesions, matrix metalloproteinase 9, and TNF-α gene expression when compared to control animals.\textsuperscript{61}

In in vitro studies, treatment with methotrexate increased the expression of the glucose transporter type 4 (GLUT4) in a mouse model of diabetes. This was associated with a significant reduction in serum glucose and insulin concentrations.\textsuperscript{62} Human studies have shown significant reductions in insulin concentrations,\textsuperscript{51,60,64–67} but not glucose concentrations,\textsuperscript{51,60,64–67} during methotrexate treatment. Contrasting results have been reported on the effects of methotrexate on glycated haemoglobin concentrations.\textsuperscript{66–68}

Cross-sectional human studies have shown trends towards lower systolic and diastolic blood pressure values in patients with rheumatoid arthritis treated with methotrexate when compared to other DMARDs or no treatment.\textsuperscript{51,69} Similar trends have been reported in prospective studies, albeit no placebo group was included.\textsuperscript{70–72} Trends towards a lower prevalence of hypertension in patients with rheumatoid arthritis treated with methotrexate, when compared to other DMARDs or no treatment, have also been reported, though no formal statistical analysis was presented.\textsuperscript{73} In a recent repeated cross-sectional study, patients with rheumatoid arthritis treated with methotrexate, with or without other DMARDs, had significantly lower clinic and 24-ambulatory systolic and diastolic blood pressure and pulse-wave velocity, a marker of arterial stiffness, when compared to patients treated with other DMARDs or no treatment (n=30).\textsuperscript{74} The association between methotrexate use and blood pressure was mediated, in univariate but not in multivariate analysis, by a single-nucleotide polymorphism of hypertension in patients with rheumatoid arthritis treated with methotrexate, when compared to other DMARDs or no treatment.\textsuperscript{75} In further analyses, methotrexate treatment prevented the temporal increase in blood pressure mediated by arterial stiffness.\textsuperscript{76}

In animal studies, treatment with methotrexate caused a significant impairment of endothelium-dependent (acetylcholine-mediated), but not endothelium-independent
(nitroprusside-mediated), vasodilatation. By contrast, no significant changes in endothelial function were observed in patients with rheumatoid arthritis or psoriasis treated with methotrexate. Other studies reported a significant improvement in endothelial function with methotrexate in patients with rheumatoid arthritis and other types of inflammatory arthritis. 

A significant reduction in measures of arterial stiffness was observed in patients with rheumatoid arthritis treated with methotrexate and infliximab, but not with methotrexate alone. By contrast, another study reported no significant changes in arterial stiffness with methotrexate.

Despite the conflicting results reported in several studies, the available evidence suggests that methotrexate might exert beneficial effects on some measures of cardiovascular risk, particularly insulin resistance, blood pressure, and, possibly, arterial stiffness.

**Putative mechanisms mediating the effects of methotrexate against atherosclerosis**

A number of mechanisms might account for the potential antiatherosclerotic, blood pressure lowering, and vasculoprotective effects of methotrexate, particularly cytokine modulation, adenosine accumulation, and activation of 5′ adenosine monophosphate-activated protein kinase.

**Cytokine modulation**

Methotrexate has been shown in vitro to increase the release of soluble TNF receptor p75 from the cell surface, with potential inhibition of the pro-inflammatory effects of TNF-α. In other studies, methotrexate treatment prevented the TNF-α-induced expression of ICAM-1 and vascular cell adhesion molecule 1, both involved in favouring the adhesion of leukocytes to the endothelium in the early stages of atherosclerosis. In animal studies, methotrexate significantly reduced the circulating concentrations of IL-6 and TNF-α. This was paralleled by a significant increase in endothelium-dependent vasodilatation and a reduction in vascular cell adhesion molecule 1. In another study, the expression of IL-6 and TNF-α was also significantly reduced by methotrexate treatment. These effects were associated with an improvement in endothelium-dependent vasodilatation in rat aorta. The inhibitory effects of methotrexate on TNF-α, IL-1, and IL-6 have also been recently reported in human macrophages. Notably, there is also preliminary evidence that the effects of methotrexate on pro-inflammatory cytokines are associated with a reduction in plaque burden. Four-week intravenous administration of methotrexate-loaded spherical polymeric nanoconstructs significantly reduced the production of IL-6 and TNF-α in apolipoprotein E-deficient (ApoE−/−) mice receiving high-fat diet. These effects were associated with a 50% reduction in plaque burden.

Other studies have reported beneficial effects of methotrexate treatment on antiatherogenic cytokines. In 24 patients with plaque psoriasis, 12-week treatment with subcutaneous methotrexate caused a trend towards an increase in IL-10, but not TGF-β, concentrations. In patients with chronic heart failure, 12-week treatment with methotrexate significantly increased the plasma concentrations of IL-10. A significant increase in IL-10 concentrations after 4- or 12-week methotrexate treatment was reported in rabbit models of in-stent neo-atherosclerosis and cardiac allograft vasculopathy, and in post-myocarditis rats. Methotrexate treatment has also been shown to increase the local adipose tissue concentrations of IL-10 in obese mice fed with high-fat diet.

**Adenosine accumulation and activation of 5′ adenosine monophosphate-activated protein kinase**

The intracellular polyglutamate forms of methotrexate inhibit the activity of the enzyme aminomimidazole carboxamide ribonucleotide (AICAR) transformylase (ATIC). The consequent accumulation of the substrate AICAR, in turn, inhibits the enzymes adenosine deaminase and adenosine monophosphate deaminase, involved in the catabolism of adenosine. Adenosine exerts blood pressure lowering effects through increased eNOS, direct vasodilation, and central nervous system pathways. Furthermore, in human studies, the pharmacological inhibition of adenosine receptors, particularly A1 and A2A, has been shown to increase blood pressure and arterial stiffness.

There is also evidence that adenosine A2B receptor activation prevents the formation of atherosclerotic lesions and reduces the plasma concentrations of cholesterol and triglycerides, possibly through the reduced activation of the transcription factor sterol regulatory element-binding protein 1 in the liver. Both AICAR and adenosine monophosphate deaminase activate the 5′ adenosine monophosphate-activated protein kinase (AMPK). AMPK protects endothelial cells against oxidative stress and apoptosis and inhibits vascular smooth muscle cell proliferation. There is increasing evidence that AICAR and/or AMPK activation stimulates NO synthesis in the endothelium, enhances endothelium-dependent and endothelium-independent vasodilation, reduces blood pressure, prevents vessel restenosis, and increases cholesterol efflux capacity. Furthermore, AMPK stimulates cellular glucose uptake, through GLUT-1 and GLUT-4 transporters, and glycolysis, providing beneficial effects on glucose homeostasis.

**Current and future research directions**

Further experimental and clinical studies are required to support the repurposing of methotrexate for the management of patients with atherosclerotic cardiovascular disease.
In particular, studies should investigate the effects of methotrexate on different cardiovascular end-points and also determine the role of pro- and antiatherogenic cytokines, adenosine, AMPK activation, methotrexate polyglutamate concentrations (a robust marker of methotrexate intracellular exposure), and genetic polymorphisms of methotrexate transporters and target enzymes, in mediating these effects. While appropriately powered trials, using either placebo or other DMARDs as comparator, should ultimately test the hypothesis that methotrexate reduces cardiovascular morbidity and mortality both in patients with and without autoimmune disorders, a number of trials addressing this issue are already in progress or have recently been completed. The results of a relatively small (n=84) study have been disappointing. The Effects of Methotrexate Therapy on ST Segment Elevation Myocardial Infarctions trial (TETHYS, clinicaltrials.gov identifier NCT01741558), investigated the role of methotrexate in reducing infarct size when administered within the first 6 hours of admission for ST-elevation myocardial infarction. Methotrexate was given as intravenous bolus, 0.05 mg/kg, immediately before percutaneous coronary intervention, followed by 0.05 mg/kg/hr for 6 hours. The infarct size in patients treated with methotrexate was not significantly different from that of patients receiving placebo. Furthermore, in univariate analysis, the left ventricular ejection at 3 months was lower in the methotrexate group when compared to the placebo group. Another study is currently investigating the effects of methotrexate carried by a lipid nanoemulsion, 40 mg/m² single dose intravenously, on left ventricular remodelling in 50 patients with anterior wall ST-elevation myocardial infarction (clinicaltrials.gov identifier NCT03516903). The recruitment for the Cardiovascular Inflammation Reduction Trial (CIRT, clinicaltrials.gov identifier NCT01594333), a large randomized placebo-controlled trial investigating whether methotrexate, 15–20 mg weekly as single oral dose, reduces a composite primary end-point of myocardial infarction, stroke, and cardiovascular death in 7,000 patients with type 2 diabetes or metabolic syndrome and stable coronary artery disease, has been prematurely stopped in April 2018. The trial has accrued enough data to answer the main question of the study and it is anticipated that the results will be presented by the end of 2018. The Inflammation and Coronary Endothelial Function in Patients with Coronary Artery Disease Trial (clinicaltrials.gov identifier NCT02366091) is investigating the effect of 15 mg oral methotrexate weekly, colchicine, and their combination on coronary endothelial function in 120 patients with established ischemic heart disease. Furthermore, the Methotrexate, Blood Pressure and Arterial Function Study (clinicaltrials.gov identifier NCT03254589) is investigating the effects of methotrexate treatment, 7.5–25 mg weekly, on clinical and 24-hour peripheral and central blood pressure in 124 patients with rheumatoid arthritis. The results of these studies will provide important additional information to support, or refute, the possible role of methotrexate in the management of patients with atherosclerotic cardiovascular disease.

**Practical considerations with the use of methotrexate in cardiovascular risk management**

Methotrexate is a relatively old drug that has been used, at high doses, for the treatment of different types of cancer and, more recently, at lower doses, for the treatment of several autoimmune disease states. Treatment with high- and low-dose methotrexate is associated with gastroenterological, haematological, renal, neurological, pulmonary, and mucocutaneous toxicity of different severity. However, with appropriate dosing and monitoring, the main side effects of methotrexate, particularly hepatic, gastrointestinal, and haematological toxicity, are infrequent and rarely severe. In a naturalistic study of 673 patients with inflammatory arthritis receiving methotrexate, mainly rheumatoid arthritis, 74% remained on treatment after 5 years. Methotrexate was stopped in 10.7% because of inefficacy or patient choice. Serious adverse events included liver abnormalities in 5.5% and haematological abnormalities in a further 5.5%. In the CareRA study of 379 patients with rheumatoid arthritis randomized to 1-year treatment with methotrexate + other DMARDs and/or corticosteroids, 2.1% reported serious adverse events. The safety profile of methotrexate in these studies compares favourably with trials of conventional cardioprotective drugs, for example, antihypertensive agents, in patient populations without autoimmune conditions. For example, in the Systolic Blood Pressure Intervention Trial in 9,069 patients with high cardiovascular risk, 9.8% (intensive treatment arm) and 7.2% (standard treatment arm) had serious adverse events. In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial in 25,620 patients with vascular disease or high-risk diabetes, serious adverse events leading to treatment discontinuation occurred in 7.2% of those randomized to ramipril, 5.1% of those randomized to telmisartan, and 12.0% of those randomized to combination treatment.

A potential advantage associated with methotrexate treatment is the once-weekly administration, either orally or subcutaneously. By contrast, virtually all cardiovascular drugs currently used require daily administration. The less-intense treatment schedule with methotrexate has the potential to increase treatment adherence, which remains a significant issue in the routine management of patients at high cardiovascular risk. For example, a recent study showed that only 49% of older patients after an acute myocardial infarction (n=90,869) were adherent to three statins. Notably, the lack of adherence to these therapies was independently associated with increased mortality (HR 1.65, 95% CI: 1.54–1.76). Similarly, a systematic review and meta-analysis reported that the non-adherence rate to secondary prevention treatment after a stroke is 30.9% (95% CI: 26.8–35.3). Repurposing methotrexate for cardiovascular risk management, at doses similar to those currently prescribed...
in patients with autoimmune disorders, would also be highly
cost effective. For example, in Australia the Prescribing Benefits
Scheme cost of methotrexate 7.5–25 mg once a week is
$94.8–109.68/year per individual patient. This is less than half
of that of atorvastatin ($222.48–258.60/year) and perindopril
($222.60–256.68/year), the most commonly prescribed statin
and ACE inhibitor in Australia, respectively. The corresponding
cost figures for methotrexate, atorvastatin, and perindopril
in the United Kingdom are £8.35–55.64/year, £7.95–22.42/year,
and £64.60–80.18/year, respectively. Notably, the yearly costs
of anakinra, a marketed IL-1 antagonist for the treatment
of rheumatoid arthritis currently under investigation as
antiatherosclerotic agent, are $514.91 in Australia and £9,568.21
in the United Kingdom.

**Conclusions**

The recognition that atherosclerosis is a chronic inflammatory
disease of the arterial wall and that significant residual
cardiovascular risk exists in a substantial number of patients
despite maximal treatment with established drugs such as
statins, beta-blockers, antiplatelets, anticoagulants, ACE
inhibitors, and ARBs, justifies the need for novel, effective
therapies that target multiple pathways, including inflammation.
Recent studies have highlighted the beneficial effects of
currently marketed anti-inflammatory drugs, such as colchicine
and hydroxychloroquine, in reducing cardiovascular events
in patients with stable coronary artery disease and in patients
with rheumatoid arthritis. Methotrexate has also the
potential to be repurposed for the management of patients with
atherosclerotic cardiovascular disease and residual cardiovascular
risk treated with currently recommended cardioprotective
agents, in view of a unique combination of anti-inflammatory
and, possibly, blood pressure lowering and vasculoprotective
effects. In this context, the identification of the patients who
are most likely to benefit from methotrexate treatment might
require additional stratification by measuring pro-atherogenic,
and possibly antiatherogenic, cytokine concentrations. However,
only after the completion of several prospective studies
investigating the effects on surrogate cardiovascular end-points
as well as morbidity and mortality, can the exact therapeutic role
of methotrexate be established in this context.

**Contributions:**
AAM wrote the first draft of the article; ST, AZ, SS, CC, MP, and GLR critically reviewed the first and subsequent drafts;
AAM wrote the final version of the article. ST, AZ, SS, CC, MP, and GLR reviewed and approved the final version.

**Disclosure and potential conflicts of interest:**
Dr Mangoni reports grants from medac GmbH (Germany), during the conduct of the study. The other authors declare that they had no conflict of interest in preparing this article. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at [http://www.drugsincontext.com/wp-content/uploads/2018/10/dic.212557-COI.pdf](http://www.drugsincontext.com/wp-content/uploads/2018/10/dic.212557-COI.pdf)

**Acknowledgments:** None.

**Funding declaration:** There was no funding associated with the preparation of this article.

**Copyright:** Copyright © 2018 Mangoni AA, Tommasi S, Zinellu A, Sotgia S, Carru C, Piga M, Erre GL. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

**Correct attribution:** Copyright © 2018 Mangoni AA, Tommasi S, Zinellu A, Sotgia S, Carru C, Piga M, Erre GL. https://doi.org/10.7573/dic.212557. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

**Article URL:** [https://www.drugsincontext.com/repurposing-existing-drugs-for-cardiovascular-risk-management-a-focus-on-methotrexate](https://www.drugsincontext.com/repurposing-existing-drugs-for-cardiovascular-risk-management-a-focus-on-methotrexate)

**Correspondence:** Arduino A Mangoni, Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University and Flinders Medical Centre, Adelaide, Australia. [arduino.mangoni@flinders.edu.au](mailto:arduino.mangoni@flinders.edu.au)

**Provenance:** invited; externally peer reviewed.

**Submitted:** 10 September 2018; **Peer review comments to author:** 15 October 2018; **Revised manuscript received:** 25 October 2018; **Accepted:** 26 October 2018; **Publication date:** 14 November 2018.

**Drugs in Context** is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief [gordon.mallarkey@bioexcelpublishing.com](mailto:gordon.mallarkey@bioexcelpublishing.com)

For all permissions, rights and reprints, contact David Hughes [david.hughes@bioexcelpublishing.com](mailto:david.hughes@bioexcelpublishing.com)

**References**

1. Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. *Circulation*. 2015;132(17):1667–1678. [http://dx.doi.org/10.1161/CIRCULATIONAHA.114.008720](http://dx.doi.org/10.1161/CIRCULATIONAHA.114.008720)

2. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. *J Am Coll Cardiol*. 2017;70(1):1–25. [http://dx.doi.org/10.1016/j.jacc.2017.04.052](http://dx.doi.org/10.1016/j.jacc.2017.04.052)
3. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165–197. http://dx.doi.org/10.1146/annurev.immunol.021908.132620

4. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–1143. PubMed PMID: 11877368

5. Gimbrone MA Jr., Garcia-Cardena G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620–636. http://dx.doi.org/10.1161/CIRCRESAHA.115.306301

6. Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of pcsk9 inhibitors. J Am Coll Cardiol. 2018;72(3):314–329. http://dx.doi.org/10.1016/j.jacc.2018.04.054

7. Lorenzatti AJ, Retzlaff BM. Unmet needs in the management of atherosclerotic cardiovascular disease: is there a role for emerging anti-inflammatory interventions? Int J Cardiol. 2021;221:581–586. http://dx.doi.org/10.1016/j.ijcard.2016.07.061

8. Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J. 2016;37(22):1723–1732. http://dx.doi.org/10.1093/eurheartj/ehw759

9. Ridker PM. From c-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145–156. http://dx.doi.org/10.1161/CIRCRESAHA.115.306656

10. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. JACC. 2011;64(3):226–235. http://dx.doi.org/10.1016/j.jacc.2018.04.054

11. Kaasenbrood L, Boekholdt SM, van der Graaf Y, et al. Distribution of estimated 10-year risk of recurrent vascular events in 114,704 European individuals: an analysis from the prospective West of Scotland Coronary Prevention Study. Circulation. 2011;123(25):2668–2676. http://dx.doi.org/10.1161/CIRCULATIONAHA.110.191278

12. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–887 e881. http://dx.doi.org/10.1016/j.amjmed.2011.12.013

13. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitric oxide and atherosclerosis: an update. Nitric Oxide. 2006;15(4):265–279. http://dx.doi.org/10.1016/j.niox.2006.03.011

14. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol. 2000;190(3):244–254. https://doi.org/10.1002/(SICI)1096-9896(20000219)190:3<244::AID-PATH575>3.0.CO;2-8

15. Maruhashi T, Soga J, Fujimura N, et al. Endothelial dysfunction, increased arterial stiffness, and cardiovascular risk prediction in patients with coronary artery disease: Fmd-j (flow-mediated dilation japan) study a. J Am Heart Assoc. 2018;7(14):pii: e008588. http://dx.doi.org/10.1016/j.jaha.2016.04.016

16. Rajasingh J, Bord E, Luedemann C, et al. Il-10-induced tnf-alpha mrna destabilization is mediated via il-10 suppression of p38 map kinase activation and inhibition of hur expression. FASEB J. 2006;20(12):2112–2114. http://dx.doi.org/10.1096/fj.06-0845fe

17. Lisinski TJ, Furie MB. Interleukin-10 inhibits proinflammatory activation of endothelium in response to borrelia burgdorferi or lipopolysaccharide but not interleukin-1beta or tumor necrosis factor alpha. J Leukoc Biol. 2002;72(3):503–511. PubMed PMID: 12223518

18. Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018;39(22):2063–2069. http://dx.doi.org/10.1093/eurheartj/ehy128

19. Joensuu JT, Aaltonen KJ, Aronen P, et al. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a register study. Rheumatology (Oxford). 2016;55(10):1803–1811. http://dx.doi.org/10.1093/rheumatology/kew264

20. Yazdany J, Dudley RA, Chen R, Lin GA, Tseng CW. Coverage for high-cost specialty drugs for rheumatoid arthritis in medicare part d. Arthritis Rheumatol. 2015;67(6):1474–1480. http://dx.doi.org/10.1002/art.39079

21. Pereira R, Faria R, Lago P, Torres T. Infection and malignancy risk in patients treated with tnf inhibitors for immune-mediated inflammatory diseases. Curr Drug Saf. 2017;12(3):162–170. http://dx.doi.org/10.2174/1574886312666170616085228

22. Winthrop KL, Mariette X, Silva JT, et al. Escmid study group for infections in compromised hosts (esgich) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [ii]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24(suppl 2):S21–S40. http://dx.doi.org/10.1016/j.cmi.2018.02.002

23. Pincus T, Gibson KA, Castrejon I. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013;71(suppl 1):S9–19. PubMed PMID: 24219036

24. Cipriani P, Ruscitti P, Carubbi F, Liakoulis V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014;10(11):1519–1530. http://dx.doi.org/10.1586/1744666X.2014.962996

25. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173–1177. http://dx.doi.org/10.1016/S0140-6736(02)08213-2

26. Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013;65(2):334–342. http://dx.doi.org/10.1002/art.37723

27. Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015;11(7):390–400. http://dx.doi.org/10.1038/nrrheum.2015.40
Methotrexate for cardiovascular risk management

28. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. http://dx.doi.org/10.1146/annurev.immunol.14.1.397

29. Stamatooulos PS, Kisats G, Papamichael CM, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol. 2009;29(10):1702–1708. http://dx.doi.org/10.1161/ATVBAHA.109.190108

30. Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117952. http://dx.doi.org/10.1371/journal.pone.0117952

31. Erre GL, Piga M, Fedele AL, et al. Prevalence and determinants of peripheral microvascular endothelial dysfunction in rheumatoid arthritis patients: a multicenter cross-sectional study. Mediators Inflamm. 2018;2018:6548715. http://dx.doi.org/10.1155/2018/6548715

32. Erre GL, Buscetta G, Palagiannis P, et al. Coronary flow reserve in systemic rheumatic diseases: a systematic review and meta-analysis. Rheumatol Int. 2018;38(7):1179–1190. http://dx.doi.org/10.1007/s00296-018-4039-8

33. Habets KL, Trouw LA, Levarht EW, et al. Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. Arthritis Res Ther. 2015;7:209. http://dx.doi.org/10.1186/s13075-015-0665-7

34. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482–487. http://dx.doi.org/10.1136/ard.2010.135871

35. Giles JT, Daniellides S, Szkoł M, et al. Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol. 2015;67(3):626–636. http://dx.doi.org/10.1002/art.38986

36. Roman MJ, Devereux RB, Schwartz JE, et al. Arterial stiffness in chronic inflammatory diseases. Hypertension. 2005;46(1):194–199. http://dx.doi.org/10.1161/01.HYP.0000168055.89955.db

37. Protogerou AD, Panagiotakos DB, Zampeli E, et al. Arterial hypertension assessed “out-of-office” in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated “white coat” phenomenon. Arthritis Res Ther. 2013;15(5):R142. http://dx.doi.org/10.1186/ar4324

38. Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2017;69(1):51–57. http://dx.doi.org/10.1002acr.23094

39. Colmegna R, Hitchon CA, Bardales MC, Puri L, Bartlett SJ. High rates of obesity and greater associated disability among people with rheumatoid arthritis in Canada. Clin Rheumatol. 2016;35(2):457–460. http://dx.doi.org/10.1007/s10067-015-3154-0

40. Hutchinson D, Shepstone L, Moots R, Lear JT, Lynch MP. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (ra), particularly in patients without a family history of ra. Ann Rheum Dis. 2001;60(3):223–227. PubMed PMID: 1171682

41. da Cunha VR, Brenol CV, Brenol JC, et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol. 2012;41(3):186–191. http://dx.doi.org/10.3109/03009742.2011.626443

42. Stella ML, Failla M, Mangoni AA, Carugo S, Giannattasio C, Mancia G. Effects of isolated systolic hypertension and essential hypertension on large and middle-sized artery compliance. Blood Press. 1998;7(2):96–102. PubMed PMID: 9657536

43. Vlachopoulos C, Aznaouridis K, O’Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31(15):1865–1871. http://dx.doi.org/10.1093/eurheartj/ehq024

44. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–1327. http://dx.doi.org/10.1016/j.jacc.2009.10.061

45. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–1370. http://dx.doi.org/10.1016/j.amjcard.2011.06.054

46. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–489. http://dx.doi.org/10.1136/annrheumdis-2014-206624

47. Heart Outcomes Prevention Evaluation Study I, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153. http://dx.doi.org/10.1056/NEJM200001203420301

48. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med. 1995;333(20):1301–1307. http://dx.doi.org/10.1056/NEJM199511163332001

49. Reiss AB, Carson SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human thp-1 monocyte/macrophages. Arthritis Rheum. 2008;58(12):3675–3683. http://dx.doi.org/10.1002/art.24040
50. Ronda N, Greco D, Adorni MP, et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. *Arthritis Rheumatol*. 2015;67(5):1155–1164. http://dx.doi.org/10.1002/art.39039

51. Rho YH, Oese P, Chung CP, Milne GL, Stein CM. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. *Arch Drug Inf*. 2009;2(2):34–40. http://dx.doi.org/10.1111/j.1753-5174.2009.00019.x

52. Rodríguez-Jimenez NA, Garcia-Gonzalez CE, Ayala-Lopez KP, et al. Modifications in lipid levels are independent of serum tnf-alpha in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy. *Biomed Res Int*. 2014;2014:510305. http://dx.doi.org/10.1155/2014/510305

53. Navarro-Millan I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. *Arthritis Rheum*. 2013;65(6):1430–1438. http://dx.doi.org/10.1002/art.37916

54. Charles-Schoeman C, Wang X, Lee YY, et al. Association of tripe therapy with improvement in cholesterol profiles over two-year followup in the treatment of early aggressive rheumatoid arthritis trial. *Arthritis Rheumatol*. 2016;68(3):577–586. http://dx.doi.org/10.1002/art.39502

55. Ormseth MJ, Yancey PG, Solus JF, et al. Effect of drug therapy on net cholesterol efflux capacity of high-density lipoprotein-enriched serum in rheumatoid arthritis. *Arthritis Rheumatol*. 2016;68(9):2099–2105. http://dx.doi.org/10.1002/art.39675

56. O’Neill F, Charakida M, Topham E, et al. Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. *Heart*. 2017;103(10):766–773. http://dx.doi.org/10.1136/heartjnl-2015-308953

57. Park YB, Choi HK, Kim MY, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. *Am J Med*. 2002;113(3):188–193. PubMed PMID: 12208376

58. Georgiadis AN, Pavasiliou EC, Lourida E, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment—a prospective, controlled study. *Arthritis Res Ther*. 2006;8(3):R82. http://dx.doi.org/10.1186/ar1952

59. Filippatos TD, Derdemezis CS, Voulgaris PV, et al. Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. *Scand J Rheumatol*. 2013;42(3):169–175. http://dx.doi.org/10.3109/03009742.2012.745013

60. Owczarczyk-Saczonek A, Drozdowski M, Maciejewska-Radomska A, Choszcz D, Placek W. The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients – preliminary report. *Postepy Dermatol Alergol*. 2018;35(1):53–59. http://dx.doi.org/10.5114/ada.2017.71358

61. Gomes FLT, Maranhao RC, Tavares ER, et al. Regression of atherosclerotic plaques of cholesterol-fed rabbits by combined chemotherapy with paclitaxel and methotrexate carried in lipid core nanoparticles. *J Cardiovasc Pharmacol Ther*. 2018;107428418778836. http://dx.doi.org/10.1177/107428418778836

62. Russo GT, Minutili L, Bitto A, et al. Methotrexate increases skeletal muscle glut4 expression and improves metabolic control in experimental diabetes. *J Nutr Metab*. 2012;2012:132056. http://dx.doi.org/10.1155/2012/132056

63. Rajappa M, Rathika S, Munisamy M, Chandrashekar L, Thappa DM. Effect of treatment with methotrexate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with psoriasis vulgaris. *J Nutr Metab*. 2012;2012:132056. http://dx.doi.org/10.1155/2012/132056

64. Wood PR, Manning E, Baker JF, et al. Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis. *World J Diabetes*. 2018;9(2):53–58. http://dx.doi.org/10.4239/wjd.v9i2.53

65. Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. No association between tnf inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin a1c and fasting glucose among psoriasis, psoriatic arthritic, and rheumatoid arthritic patients. *J Drugs Dermatol*. 2015;14(2):159–166. PubMed PMID: 25689811

66. Rekedal LR, Massarotti E, Garg R, et al. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. *Arthritis Rheum*. 2010;62(12):3569–3573. http://dx.doi.org/10.1002/art.27703

67. Perdan-Pirkmajer K, Pirkmajer S, Thevis M, et al. Methotrexate reduces hba1c concentration but does not produce chronic accumulation of zmp in patients with rheumatoid or psoriatic arthritis. *Scand J Rheumatol*. 2016;45(5):347–355. http://dx.doi.org/10.3109/03009742.2015.1105290

68. Cuchacovich R, Espinoza LR. Does tnf-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (ra) patients? *Clin Rheumatol*. 2009;28(10):1217–1220. http://dx.doi.org/10.1007/s10067-009-1208-x
Methotrexate for cardiovascular risk management

Mangoni AA, Tommasi S, Zinellu A, Sotgia S, Carru C, Piga M, Erre GL. Drugs in Context 2018; 7: 212557. DOI: 10.7573/dic.212557

89. Gong K, Zhang Z, Sun X, et al. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure.

88. Stigliano C, Ramirez MR, Singh JV, et al. Methotraxate-loaded hybrid nanoconstructs target vascular lesions and inhibit atherosclerosis progression in apoE(-/-) mice.

87. Municio C, Dominguez-Soto A, Fuentelsaz-Romero S, et al. Methotrexate limits inflammation through an a20-dependent cross-talk mechanism.

86. Ma Y, Li L, Shao Y, Bai X, Bai T, Huang X. Methotrexate improves perivascular adipose tissue/endothelial dysfunction via amending detrimental changes in some antioxidant parameters, systemic cytokines and fat production.

85. Quan A, Pan Y, Singh KK, et al. Cardiovascular inflammation is reduced with methotrexate in diabetes.

84. Yamasaki E, Soma Y, Kawa Y, Mizoguchi M. Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by cultured human umbilical vein endothelial cells.

83. Edwards CK 3rd, Bendele AM, Reznikov LI, et al. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous atherosclerosis progression in apoe(-/-) mice.

82. Seitz M, Zwicker M, Loetscher P. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes.

81. Vassilopoulos D, Gravos A, Vlachopoulos C, et al. Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis.

80. Deyab G, Hokstad I, Whist JE, et al. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.

79. Hjeltnes G, Hollan I, Forre O, et al. Relations of serum comp to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and tnf-alpha inhibitors.

78. Galarraga B, Belch JJ, Pullar T, Ogston S, Khan F. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antiathericogenic therapy.

77. El-Gowilly SM, Helmy MM, El-Gowelli HM. Pioglitazone ameliorates methotrexate-induced renal endothelial dysfunction via activation of AMPK/Enos pathway.

76. Woodman RJ, Baghdadi LR, Shanahan ME, Mangoni AA. The temporal relationship between arterial stiffening and blood pressure is modified by methotrexate treatment in patients with rheumatoid arthritis.

75. Baghdadi LR, Woodman RJ, Shanahan ME, Wiese MD, Mangoni AA. Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study.

74. Mangoni AA, Baghdadi LR, Shanahan EM, et al. Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study.

73. van Halm VP , Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.

72. Baker JF, Sauer B, Teng CC, et al. Initiation of disease-modifying therapies in rheumatoid arthritis is associated with changes in blood pressure.

71. Tam LS, Shang Q, Li EK, et al. Inflimbiab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis – a randomized trial.

70. Gyldenlove M, Jensen P, Lovendorf MB, Zachariae C, Hansen PR, Skov L. Short-term treatment with methotrexate does not affect microvascular endothelial function in patients with psoriasis.
92. Zhang Z, Zhao P, Li A, et al. Effects of methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats. *Mediators Inflamm.* 2009;2009:389720. [http://dx.doi.org/10.1155/2009/389720](http://dx.doi.org/10.1155/2009/389720)

93. DeOliveira CC, Acedo SC, Gotardo EM, et al. Effects of methotrexate on inflammatory alterations induced by obesity: an in vivo and in vitro study. *Mol Cell Endocrinol.* 2012;361(1–2):92–98. [http://dx.doi.org/10.1016/j.mce.2012.03.016](http://dx.doi.org/10.1016/j.mce.2012.03.016)

94. Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. *Drug Metab Pharmacokinet.* 2014;29(1):12–19. PubMed PMID: 24284432

95. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. *Am J Cardiol.* 1997;79(12A):2–10. PubMed PMID: 9223356

96. Olsson RA, Pearson JD. Cardiovascular purinoceptors. *Physiol Rev.* 1990;70(3):761–845. [http://dx.doi.org/10.1152/phyrev.1990.70.3.761](http://dx.doi.org/10.1152/phyrev.1990.70.3.761)

97. Stella L, de Novellis V, Marabese I, et al. The role of a3 adenosine receptors in central regulation of arterial blood pressure. *Br J Pharmacol.* 1998;125(3):437–440. [http://dx.doi.org/10.1038/bj.0702126](http://dx.doi.org/10.1038/bj.0702126)

98. Schindler CW, Karcz-Kubicha M, Thormidek EB, et al. Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine a1 and a2a subtype receptor agonists. *Br J Pharmacol.* 2005;144(5):642–650. [http://dx.doi.org/10.1038/sj.bjp.0706043](http://dx.doi.org/10.1038/sj.bjp.0706043)

99. Mahmud A, Feely J. Acute effect of caffeine on arterial stiffness and aortic pressure waveform. *Hypertension.* 2001;38(2):227–231. PubMed PMID: 11509481

100. Koupelova M, Johnston-Cox H, Ravid K. Regulation of atherosclerosis and associated risk factors by adenosine and adenosine receptors. *Curr Atheroscler Rep.* 2012;14(5):460–468. [http://dx.doi.org/10.1007/s11883-012-0263-y](http://dx.doi.org/10.1007/s11883-012-0263-y)

101. Varani K, Portaluppi F, Merighi S, Ongini E, Borea PA. Caffeine alters a2a adenosine receptors and their function in human platelets. *Circulation.* 1999;99(19):2499–2502. PubMed PMID: 10330379

102. Hardie DG. Amp-activated protein kinase: an energy sensor that regulates all aspects of cell function. *Genes Dev.* 2011;25(18):1895–1908. [http://dx.doi.org/10.1101/gad.17420111](http://dx.doi.org/10.1101/gad.17420111)

103. Antonioli L, Colucci R, Pellegrini C, et al. The ampk enzyme-complex: from the regulation of cellular energy homeostasis to a pharmacological target? *Expert Opin Ther Targets.* 2016;20(2):179–191. [http://dx.doi.org/10.1517/14728222.2016.1086752](http://dx.doi.org/10.1517/14728222.2016.1086752)

104. Boin F, Erre GL, Posadino AM, et al. Oxidative stress-dependent activation of collagen synthesis is induced in human pulmonary smooth muscle cells by sera from patients with scleroderma-associated pulmonary hypertension. *Orphanet J Rare Dis.* 2014;9:123. [http://dx.doi.org/10.1186/s13023-014-0123-7](http://dx.doi.org/10.1186/s13023-014-0123-7)

105. Igata M, Motoshima H, Tsuruzoe K, et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. *Circ Res.* 2005;97(8):837–844. [http://dx.doi.org/10.1161/01.RES.0000185823.73556.06](http://dx.doi.org/10.1161/01.RES.0000185823.73556.06)

106. Li J, Wang Y, Wang Y, et al. Pharmacological activation of ampk prevents drp1-mediated mitochondrial fission and alleviates endoplasmic reticulum stress-associated endothelial dysfunction. *J Mol Cell Cardiol.* 2015;86:62–74. [http://dx.doi.org/10.1016/j.yjmcc.2015.07.010](http://dx.doi.org/10.1016/j.yjmcc.2015.07.010)

107. Chen Z, Peng IC, Sun W, et al. Amp-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase ser633. *Circ Res.* 2009;104(4):496–505. [http://dx.doi.org/10.1161/CIRCRESAHA.108.187567](http://dx.doi.org/10.1161/CIRCRESAHA.108.187567)

108. Goirand F, Solar M, Athea Y, et al. Activation of amp kinase alpha1 subunit induces aortic vasorelaxation in mice. *J Physiol.* 2007;581(Pt 3):1163–1171. [http://dx.doi.org/10.1113/jphysiol.2007.132589](http://dx.doi.org/10.1113/jphysiol.2007.132589)

109. Nagata D, Takeda R, Sata M, et al. Amp-activated protein kinase inhibits angiostatin ii-stimulated vascular smooth muscle cell proliferation. *Circulation.* 2004;110(4):444–451. [http://dx.doi.org/10.1161/01.CIR.0000136025.96811.76](http://dx.doi.org/10.1161/01.CIR.0000136025.96811.76)

110. Ford RJ, Teschke SR, Reid EB, Durham KK, Kroetsch JT, Rush JW. Amp-activated protein kinase activator aicar acutely lowers blood pressure and relaxes isolated resistance arteries of hypertensive rats. *J Hypertens.* 2012;30(4):725–733. [http://dx.doi.org/10.1097/01.HJH.000032835050ca](http://dx.doi.org/10.1097/01.HJH.000032835050ca)

111. Buhl ES, Jessen N, Pold R, et al. Long-term aicar administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. *Diabetes.* 2002;51(7):2199–2206. PubMed PMID: 12086950

112. Angin Y, Beauloye C, Horman S, Bertrand L. Regulation of carbohydrate metabolism, lipid metabolism, and protein metabolism by ampk. *Exs.* 2016;107:23–43. [http://dx.doi.org/10.1007/978-3-319-43589-3_2](http://dx.doi.org/10.1007/978-3-319-43589-3_2)

113. Malik F, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. *Pharmacogenomics.* 2013;14(3):305–314. [http://dx.doi.org/10.2217/pgs.12.214](http://dx.doi.org/10.2217/pgs.12.214)

114. Moreira DM, Lueneberg ME, da Silva RL, Fattah T, Gottschall CAM. Methotrexate therapy in st-segment elevation myocardial infarctions: a randomized double-blind, placebo-controlled trial (methy trial). *J Cardiovasc Pharmacol Ther.* 2017;22(6):538–545. [http://dx.doi.org/10.1074/jcpt.201744817699884](http://dx.doi.org/10.1074/jcpt.201744817699884)

115. Husten L. Nih halts large cardiovascular inflammation reduction (cirt) trial. *CardioBrief.* 2018. [http://www.cardiobrief.org/2018/05/21/nih-halts-large-cardiovascular-inflammation-reduction-cirt-trial/](http://www.cardiobrief.org/2018/05/21/nih-halts-large-cardiovascular-inflammation-reduction-cirt-trial/). Accessed July 26, 2018.
116. Benedek TG. Methotrexate: from its introduction to non-oncologic therapeutics to anti-tnf-alpha. *Clin Exp Rheumatol*. 2010;28(Suppl 61):S3–8. PubMed PMID: 21044425

117. Malaviya AN. Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story. *Int J Rheum Dis*. 2016;19(9):844–851. http://dx.doi.org/10.1111/1756-185X.12862

118. Bertino JR. Kamarovsky memorial lecture. Ode to methotrexate. *J Clin Oncol*. 1993;11(5):5–14. http://dx.doi.org/10.1200/JCO.1993.11.1.5

119. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. *Oncologist*. 2016;21(12):1471–1482. http://dx.doi.org/10.1634/theoncologist.2015-0164

120. Romao VC, Lima A, Bernardes M, Canhao H, Fonseca JE. Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? *Immunol Res*. 2014;60(2–3):289–310. http://dx.doi.org/10.1007/s12026-014-8564-6

121. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. *Rheumatology (Oxford)*. 2005;44(1):61–66. http://dx.doi.org/10.1093/rheumatology/keh512

122. Verschueren P, De Cock D, Corluy L, et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (cobra slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of carera, a randomised pragmatic open-label superiority trial. *Ann Rheum Dis*. 2017;76(3):511–520. http://dx.doi.org/10.1136/annrheumdis-2016-209212

123. Group SR, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015;373(22):2103–2116. http://dx.doi.org/10.1056/NEJMoa1511939

124. Investigators O, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008;358(15):1547–1559. http://dx.doi.org/10.1056/NEJMoa0801317

125. Korhonen MJ, Robinson JG, Annis IE, et al. Adherence tradeoff to multiple preventive therapies and all-cause mortality after acute myocardial infarction. *J Am Coll Cardiol*. 2017;70(13):1543–1554. http://dx.doi.org/10.1016/j.jacc.2017.07.783

126. Al AlShaikh S, Quinn T, Dunn W, Walters M, Dawson J. Predictive factors of non-adherence to secondary preventative medication after stroke or transient ischaemic attack: a systematic review and meta-analyses. *Eur Stroke J*. 2016;1(2):65–75. http://dx.doi.org/10.1177/2396987316647187

127. Nidorf SM, Eikelboom JW, Budgen CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. *J Am Coll Cardiol*. 2013;61(4):404–410. http://dx.doi.org/10.1016/j.jacc.2012.10.027

128. Sharma TS, Wasko MC, Tang X, et al. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. *J Am Heart Assoc*. 2016;5(1):pii: e002867. http://dx.doi.org/10.1161/JAHA.115.002867

129. Shapiro M, Levy Y. The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients. *Oncotarget*. 2018;9(5):6615–6622. http://dx.doi.org/10.18632/oncotarget.23570

130. Floris A, Piga M, Mangoni AA, Bortoluzzi A, Erre GL, Cau A. Protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus. *Mediators Inflamm*. 2018;2018:3424136. http://dx.doi.org/10.1155/2018/3424136